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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbid-
ity, mortality, and health care expenditure worldwide. Relaxation of airway smooth muscle 
with inhaled bronchodilators is the cornerstone of treatment for stable COPD, with inhaled 
corticosteroids reserved for those with a history of exacerbations. Tiotropium has occupied 
center stage in COPD treatment for over 10 years and improves lung function, quality of life, 
exercise endurance, and reduces the risk of COPD exacerbation. Long-acting β
2
-agonists 
(LABAs) improve lung function, reduce dynamic hyperinflation, increase exercise tolerance, 
health-related quality of life, and reduce acute exacerbation of COPD. The combination of 
long-acting muscarinic antagonists (LAMAs) and LABAs is thought to leverage different 
pathways to induce bronchodilation using submaximal drug doses, increasing the benefits and 
minimizing receptor-specific side effects. Umeclidinium/vilanterol is the first combination 
of LAMA/LABA to be approved for use in stable COPD in USA and Europe. Additionally, 
indacaterol/glycopyrronium and aclidinium/formoterol have been approved in Europe and in 
numerous locations outside USA. Several other agents are in the late stages of development, 
most of which offer once-daily dosing. The benefits of new LAMA/LABA combinations 
include improved pulmonary function, dyspnea, and health-related quality of life, and in some 
cases, reduced exacerbations. These evolving treatments will provide new opportunities and 
challenges in the management of COPD.
Keywords: bronchodilator, fixed-dose combination, chronic bronchitis, emphysema, COPD 
treatment
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of suffering and 
is an increasing burden to patients and society. Mortality due to COPD is projected 
to increase to become the third most common cause of death worldwide by 2030.1,2 
The array of available inhaled medications is increasing; a number of new agents are 
either recently approved or are in late-stage clinical trials. In this paper, we will review 
the current and emerging evidence for combining long-acting muscarinic antagonists 
(LAMAs) with long-acting β
2
-agonists (LABAs) in COPD.
Pathogenesis
The pathogenesis of COPD is understood to be an inflammatory response to inhaled 
particles, the most important of which is tobacco smoke.3 Exposure to other respiratory 
irritants such as burned biomass fuels and vocational dusts are significant risk factors 
for COPD.4,5 In susceptible persons, respiratory irritants precipitate an inflammatory 
response leading to local inflammation causing pulmonary disease clinically recognized 
as COPD. The subtypes of chronic bronchitis and emphysema are often described, 
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although with a few exceptions, the distinction lacks therapeu-
tic inference. Pathologically, one observes varying degrees 
of airway narrowing, mucus hypersecretion, and loss of 
small conducting airways.6 Normal pulmonary physiology 
is substantially altered in COPD such that the small airways 
(,2 mm) become the major site of airflow resistance.
These anatomic changes lead to expiratory airflow 
limitation, air trapping, and ventilation–perfusion mismatch.7 
Additionally, the loss of elastic recoil and hyperinflation 
adversely affect thoracic and diaphragmatic mechanics, 
increasing the work of breathing, and ultimately leading to 
dynamic hyperinflation.8 Hyperinflation is an independent 
predictor of mortality in COPD.9 Treatment with inhaled 
bronchodilators can reduce hyperinflation, improve dyspnea 
and increase exercise tolerance.10
Spirometry remains the gold standard diagnostic test, and 
although controversy remains regarding the use of a fixed 
ratio or lower limit of normal, a reduced FEV
1
 (forced expira-
tory volume in the first second)/FVC (forced vital capacity) 
ratio not fully reversed with bronchodilators is required to 
confirm a clinical diagnosis.11,12 The severity of COPD was 
previously grouped by airflow limitation, but since 2011, 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) report has advised using the Combined COPD 
Assessment Test (CAT), placing patients into a multidimen-
sional grouping algorithm (A–D) determined by symptoms, 
breathlessness, and risk of exacerbation. Symptom burden is 
measured by the CAT score and breathlessness is measured 
by the modified Medical Research Council dyspnea scale. 
Risk of exacerbation is determined by exacerbation history 
in the preceding year and FEV
1
. Although reduced FEV
1
 
is independently associated with increased mortality, the 
association between FEV
1
 and dyspnea is poor.11
Burden
Broadly speaking, the chronic course of COPD is character-
ized by dyspnea, exercise limitation, cough, sputum expec-
toration, and wheezing. These symptoms vary substantially 
from patient to patient and day to day. The chronic course 
is punctuated, at least in some individuals, with acute 
exacerbations of chronic obstructive pulmonary disease 
(AECOPD). AECOPD are associated with a decreased qual-
ity of life (QOL),13 a modestly accelerated loss of FEV
1
,14 
and increased mortality. Those who are hospitalized for 
AECOPD are at increased risk of 1 year mortality of at 
least 18%.15 Furthermore, greater frequency and severity 
of AECOPD are independently associated with increased 
mortality.16 In a recent report from the ECLIPSE cohort, a 
greater frequency of exacerbation has been described to be 
a stable phenotype over time.17 Costs associated with COPD 
are substantial, estimated to be over $50 billion, the majority 
is spent treating acute exacerbations.18
Respiratory symptoms, even in smokers, are poor pre-
dictors of a diagnosis of COPD,19 and up to 50% of COPD 
cases are not recognized and treated. In a prevalence study 
of over 9,000 adults in 12 countries, stage II (moderate) or 
greater COPD was identified in 10%. This study included 
both never, former, and active smokers.20 Furthermore, Buist 
et al20 identified stage II or greater COPD in 3%–11% in never 
smokers. A recent report from the ECLIPSE study showed 
that 22% of patients with stage II COPD experienced frequent 
exacerbations,17 indicating a higher risk phenotype.
Increasingly, COPD is recognized to be associated with 
other illnesses remote to the lung itself. In addition to the 
apparent increase in lung cancer observed in smokers, we 
now recognize that patients with COPD have a substantial 
burden of cardiovascular, metabolic, musculoskeletal, and 
other diseases.21 These diseases must be recognized in clinical 
practice in order to optimize the safety of treatments and most 
directly address the mechanism of the patient’s symptoms 
and physiology. For example, dyspnea or fatigue may be 
mediated by dynamic hyperinflation and poor muscle func-
tion in a given individual. Despite improvements in FEV
1
 
and inspiratory capacity, dyspnea due to muscle weakness 
will be unresponsive to optimal bronchodilation.
Overview of treatment
Inhaled bronchodilators are the central therapeutic agents for 
COPD. Comprehensive treatment includes numerous other 
measures guided by the needs and goals of the specific patient, 
the most critical of which are smoking prevention and cessa-
tion. The array of other treatments includes pulmonary reha-
bilitation, infection prevention with immunizations, inhaled 
corticosteroids (ICS), and adjunctive medications, such as 
phosphodiesterase-4 inhibitors (theophylline or roflumilast), 
macrolides, and oxygen. Lung volume reduction and lung trans-
plantation are surgical options in appropriate patients.11,12
Airway tone is controlled by both the sympathetic and 
parasympathetic nervous systems. These mechanisms inter-
act and may potentiate each other, and are employed alone or 
in combination therapeutically. Relaxation of airway smooth 
muscle is caused by blockade of acetylcholine activity at 
the receptor (muscarinic antagonist) or stimulation of the 
G protein-coupled receptor (β-agonist).22 The resting airway 
tone is mediated by the parasympathetic system, which is 
delivered to the airways via the vagus nerve. Acetylcholine 
international Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
787
Dual therapy for COPD: the scientific rationale for LAMA + LABA
receptors (AChRs) have been identified in the large and small 
airways, glandular and epithelial cells, as well as multiple 
other cells of the lung. Stimulation of the AChR causes 
increased tone in airway smooth muscle, and blockade of 
AChR reduces airway tone. Direct sympathetic innervation 
has been identified in submucosal tissue, lung vasculature, 
and inflammatory cells, but is nearly absent in airway smooth 
muscle cells. Although β-adrenergic receptors can be identi-
fied in the airway smooth muscle cell, innate physiologic 
stimulation of the airway smooth muscle β-adrenergic recep-
tors requires circulating sympathetic mediators. Currently, 
inhaled β-agonists are used therapeutically to stimulate this 
receptor to cause bronchodilation. This method of inhaled 
topical delivery reduces side effects when compared to 
intravenous treatment with β-agonists.
Anticholinergic drugs in the form of smoked alkaloids 
were among the first effective treatments for asthma,23 and 
in the early 19th century, the smoking of asthma cigarettes 
containing Datura ferox or Datura stramonium was widely 
popular. In the mid-20th century, parenteral muscarinic 
antagonists and β-agonists were used for acute attacks of 
asthma.24 Parenteral delivery was associated with side effects 
and a short duration of benefit. As such, subsequent work 
has both optimized the receptor specificity and the duration 
of action. The LAMA, tiotropium (TIO), was approved by 
the US Food and Drug Administration (FDA) in 2004 and 
has occupied a central role in the management of COPD for 
the last decade. The FDA has approved two other LAMAs, 
aclidinium (ACL) in 2012,25 and umeclidinium (UMEC) in 
2014.26
β-agonists were in use in Chinese medicine for millennia 
in the form of ephedra. Developments in the mid-20th century 
yielded compounds that specifically target the β
2
-adrenergic 
receptor, reducing the side effects from β
1
-agonists.22 Further 
work yielded the LABAs, salmeterol, and formoterol (FOR). 
More recent agents such as indacaterol have been developed 
which last 24 hours, providing new prospects for once-daily 
combination therapy in fixed combinations. LAMA/LABA 
combinations currently approved or in development are 
listed in Table 1.
Comments on study outcome 
measures
Interpretation of study results is oriented around the unique 
perspective of the stakeholder, the relative value of a given 
outcome may differ from the view of the patient, physician, 
third party payer, etc.27 The informed viewpoint of the patient 
should remain central to framing the relative benefits and 
costs of treatments. Study endpoints are optimally interpreted 
using the minimal clinically important difference (MCID) 
rather than statistical differences alone. These endpoints have 
been reviewed recently and are summarized in Table 2.27–30 
The MCID has several limitations that are important to con-
sider. First, the MCID cannot be verified against objective 
standards and is thus dependent on subjective value judg-
ments. Second, some endpoints are affected by time, and bias 
may be introduced by the duration of a trial.29 The interval 
benefit of a combination therapy is unlikely to be as great as 
the benefit of adding a single agent to placebo (PCBO). Jones 
et al29 propose that the proportion of those meeting the MCID 
criteria should be compared rather than the group means. The 
relative worthwhile change using responder analysis has not 
been established in COPD, and the term “minimal worthwhile 
incremental advantage” has been proposed.29
An ideal therapy in COPD would reduce mortality and 
dyspnea, increase exercise tolerance, increase QOL, and 
reduce the frequency and severity of exacerbations and hos-
pitalizations. The cost of maintenance therapies is a critical 
consideration, both in wealthy and developing countries. 
Ideal therapies would additionally reduce the overall cost 
of treating COPD. Reduction in exacerbation frequency has 
been reported with both FOR and salmeterol,18 TIO,31 and 
Table 1 Regulatory status of fixed dose LAMA/LABA combinations
Drug Trade name Approved dose Approval status
Umeclidinium/vilanterol Anoro™
ellipta®
62.5/25 μg once daily (USA)
55/22 μg once daily (europe)
FDA approved 2013
eMA positive opinion 2014
QvA149 Ultibro®
Breezhaler®
85/43 μg once daily – europe,  
Canada, Japan, Latin America
eMA positive opinion 2013,
FDA application complete  
for 27.5/12.5 μg twice daily
Aclidinium/formoterol Brimica®, Genuair® 340/12 μg twice daily eMA positive opinion 2014
Tiotropium/olodaterol Stiolto™, Respimat® 2.5/2.5 μg two puffs once daily FDA approved 2015
Glycopyrronium/formoterol – – –
Abbreviations: eMA, european Medicines Agency; FDA, US Food and Drug Administration; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; 
QVA149, indacaterol/glycopyrronium.
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fixed combinations of inhaled salmeterol–fluticasone or 
budesonide–FOR.32,33 We will review the evidence for newer 
combinations of LAMA/LABA.
Combination of short-acting 
bronchodilators and approved 
LAMA/LABAs: an overview
Multiple lines of evidence support the physiologic rationale, 
clinical efficacy, and safety of combining anticholinergic 
and β
2
-agonist bronchodilators. The pharmacology of bron-
chodilators and the scientific rationale for the combination 
of LAMAs and LABAs has been extensively reviewed by 
Cazzola et al22 and Cazzola and Molimard.34 By leveraging 
different receptor types at submaximal doses, combination 
agents may increase therapeutic benefits while minimizing 
dose-dependent side effects. Pragmatically, consolidating 
treatments into single devices ought to decrease the complex-
ity of usage, easing the burden on patients who are typically 
treated for multiple different conditions other than COPD.
The combination of short-acting muscarinic antago-
nist ipratropium bromide and the short-acting β
2
-agonist 
(SABA) albuterol (ALB) was described in two trials of the 
inhaler, COMBIVENT,35 and the nebulized preparation.36 
Compared to the single components, ipratropium bromide + 
ALB provided significant improvements in FEV
1
 peak, FEV
1
 
area under the curve (AUC), and FVC with a similar safety 
profile.35 The clinical changes noted by the patients and the 
study teams were not significantly different; however, as the 
authors note, the baseline symptoms were mild. Further stud-
ies demonstrated that the combination of LAMA and LABA 
in separate devices (free combinations) were beneficial. For 
example, when compared to salmeterol 50 μg twice daily or 
TIO 18 μg daily, the combination of both drugs increased 
trough FEV
1
 (103–125 mL, P#0.05), FVC (171–226 mL, 
P#0.05), significantly improved dyspnea (P,0.005), and 
reduced the amount of rescue salbutamol (P,0.005) required, 
without reducing safety compared to monocomponents.37
Combinations of long-acting bronchodilators are recom-
mended for patients who remain symptomatic despite the use 
of a single long-acting bronchodilator. In patients without 
exacerbations, the ICS are not typically recommended. 
Currently, several combination medications are in various 
stages of development, and clinicians and patients have 
expanding options in selecting LAMA/LABA combinations. 
Selected reported outcomes are summarized in Table 3.
The future: LAMA/LABA
Umeclidinium/vilanterol
Umeclidinium/vilanterol (UMEC/VI) is the first fixed 
LAMA/LABA combination to garner approval by the FDA 
and has achieved a favorable review from the European 
Medicines Agency (EMA). It has been approved in Europe 
at 55/22 μg dose, in the US at 62.5/25 μg, and is a dry pow-
der inhaler (DPI) dosed one inhalation daily. The reported 
efficacy of UMEC/VI is summarized in Table 3. A dose 
ranging study of UMEC identified that once-daily dosing at 
62.5 or 125 μg was optimal.38 VI doses of 25 or 50 μg have 
been identified to be optimal in terms of increasing FEV
1
 and 
had a safety profile similar to PCBO.39 When UMEC and VI 
were administered in combination by the inhaled route, the 
pharmacokinetics of each component was similar to those 
observed when each active substance was administered sepa-
rately. The predispensed dose is 74.2 μg equivalent to 62.5 μg 
of UMEC and 25 μg of VI. The delivered dose leaving the 
mouthpiece is UMEC 55 μg and VI 22 μg.
Both are stable when given in combination. The abso-
lute bioavailability of UMEC is 13% and VI, 27%. As for 
biotransformation, UMEC is metabolized by the cytochrome 
P4502D6 (CYP2D6), while VI is metabolized by P4503A4 
(CYP3A4). In contrast to indacaterol/glycopyrronium 
(QVA149), there is an interaction. In order to match the fine 
particle doses in the combination, the dose of indacaterol 
was adjusted from 75 to 55 μg.40,41 Similar considerations are 
applicable for other combination products. Initial safety stud-
ies of a fixed combination of UMEC/VI 500/25 μg once daily 
vs PCBO for 28 days showed that UMEC/VI did not change 
Table 2 Selected outcomes and definition of significant differences
Outcome MCID Comments
Trough Fev1 100 mL No MCID established  
for AUC, FvC
Health-related  
quality of life
SGRQ: 4 units Higher score indicate  
poorer health status
Dyspnea TDi $1 unit –
Rescue medication 
use
No validated  
MCiD
–
Exacerbations 1 exacerbation/year, 
22% reduction
Definition of AECOPD  
varies. Seasonal variation 
in frequency impacts  
studies ,12 months
Daily respiratory  
symptoms
e-RS total .-2 Suggested responder  
definition
Notes: The MCID was developed for comparison between an active treatment and 
placebo; MCID comparing active treatments is not defined. Copyright © 2011. Future 
Science Ltd. Adapted from Miles MC, Donohue JF, Ohar JA. Combination therapy for 
COPD: emerging evidence from recent clinical trials. J Clin Invest, 2011;1(6):879–890 with 
permission of Future Science Ltd.27 Additional data from Cazzola et al28 and Leidy et al.30
Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary 
disease; AUC, area under the curve; e-RS total, eXACT respiratory symptoms total 
score; Fev1, forced expiratory volume in the first second; FVC, forced vital capacity; 
MCiD, minimal clinically important difference; SGRQ, St George Respiratory 
Questionnaire; TDi, transition dyspnea index.
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pulse, blood pressure, or the QT interval. The emergence of 
clinically significant abnormalities in Holter monitors was 
similar in the PCBO arm and the UMEC/VI arm.42 Subsequent 
trials have investigated doses ranging from UMEC 62.5 to 
125 μg in a fixed combination with VI 25 μg.
In the first efficacy trial, UMEC/VI 62.5/25 μg was 
compared to UMEC 62.5 μg, VI 25 μg, and PCBO over 
6 months.43 Despite improvements in FEV
1
 and FVC in the 
dual therapy arm vs UMEC and VI, dyspnea and QOL were 
similar in all active treatment groups. Although not designed 
or powered to study AECOPD, treatment with UMEC/VI but 
not UMEC or VI resulted in a lower risk of COPD exacer-
bations with a hazard ratio (HR) of 0.5 (P#0.01) compared 
to PCBO. Safety was similar in all groups, and there was a 
low incidence of anticholinergic symptoms (,3%) similar 
to PCBO. Beta effects were not different in groups treated 
with VI than PCBO. Interestingly, the UMEC/VI had the 
lowest withdrawal rate (20%) compared to PCBO (27%). 
Furthermore, 13% of the PCBO withdrew for lack of efficacy 
compared to 5% in the UMEC/VI group.
Decramer et al44 reported a paired 24-week trial compar-
ing two doses of UMEC/VI (125/25 and 62.5/25 μg) with 
TIO 18 μg, UMEC 125 μg, and VI 25 μg. Both doses of 
UMEC/VI produced greater improvements in trough FEV
1
 
compared to VI or TIO, but did not improve FEV
1
 compared 
to UMEC monotherapy.44 In contrast to the improvements 
in FEV
1
, symptom scores and health-related quality of life 
(HRQOL) were similar between groups. Furthermore, the rate 
of exacerbation was similar over the 6-month study. Safety 
was similar between groups; however, numerically, more 
patients in the UMEC/VI groups withdrew from the study. 
The authors concluded that UMEC/VI is beneficial in that it 
produced improvements in lung function with similar safety. 
In an accompanying editorial, the lack of significant difference 
in symptoms or exacerbations compared to TIO alone was 
referenced as a call to develop drugs that would impact these 
patient-centered outcomes, rather than lung function alone.45
Two more trials investigating the doses of UMEC/VI 
125/25 μg were reported in 2014. We will review these 
studies for evidence of efficacy and safety, although the 
reader is reminded that the approved dose is 62.5/25 μg in 
the US and 55/22 μg in Europe.
The first study of 563 patients reported by Donohue et al46 
reported the safety of UMEC/VI 125/25 μg compared to 
UMEC 125 and PCBO for 1 year. Overall, adverse events and 
serious adverse events were similar in all groups. UMEC mono-
therapy caused more atrial arrhythmias on electrocardiogram 
and Holter monitors, but as these events were asymptomatic, 
the clinical significance was questioned. Although the study 
was not designed or powered to detect changes in exacerba-
tion frequency or lung function, the trend in exacerbation 
deserves mention. Fewer patients had COPD exacerbations 
in the UMEC/VI (13%) and UMEC (15%) groups compared 
to PCBO (24%), translating into fewer hospitalizations in the 
active treatment groups (6%–7%) vs PCBO (12%).
In a 6-month study comparing UMEC/VI 125/25 μg to 
UMEC 125 μg, VI 25 μg, and PCBO, UMEC/VI improved 
trough FEV
1
 238 mL vs PCBO, 79 mL vs UMEC, and 
114 mL vs VI (P#0.001 for all). UMEC/VI improved dys-
pnea and HRQOL more than PCBO or monocomponents, 
but the improvements were less than the MCIDs. All active 
treatments lowered the risk of AECOPD with a HR of 0.4–0.5 
compared to PCBO.47 The reader is reminded that this trial 
tested a dose of UMEC/VI that is above the doses approved 
by the EMA and FDA.
Taken together, UMEC/VI appears to be safe, pro-
duces greater improvements in lung function compared to 
monocomponents, and in some studies reduces the risk of 
exacerbations. UMEC/VI has not, however, shown dramatic 
improvements in dyspnea or HRQOL compared to TIO or 
the components UMEC or VI.
Indacaterol/glycopyrronium
Indacaterol/glycopyrronium (QVA149) is a DPI containing 
indacaterol 110 μg and glycopyrronium (GLY) 50 μg taken 
once daily, marketed as Ultibro Breezhaler (Novartis Phar-
maceuticals UK Ltd, Surrey, UK). The EMA recommended 
that Ultibro Breezhaler be granted marketing authorization 
in 2013;48 Novartis completed an application to the FDA.49 
The component indacaterol has been approved by EMA and 
FDA,50,51 and GLY was approved by EMA52 for use in stable 
COPD. The efficacy of QVA149 (50 μg DPI once daily) has 
been reported in a series of Phase III clinical trials under the 
IGNITE (Indacaterol and GlycopyrroNium bromide ClInical 
sTudiEs) program funded by Novartis Pharmaceuticals. The 
findings of the studies are summarized in Table 3.
Safety and efficacy of QVA149 were tested in the 
ENLIGHTEN trial, a 52-week randomized, PCBO-controlled 
trial in patients with moderate-to-severe COPD.53 At 52 
weeks trough FEV
1
 was increased 189 mL with QVA149 vs 
PCBO (P,0.001), rescue SABA use was reduced, and some 
symptom scores were improved with QVA149. Overall, the 
incidence of AEs was similar between groups. Numerically, 
more serious adverse events occurred in the QVA149 group; 
however, it did not meet statistical significance (P=0.07). At 
baseline, the group given QVA149 had more severe COPD, 
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more comorbidities (diabetes, myocardial infarction, and 
stroke), and a greater frequency of ICS prescription. The 
authors proposed that the numerical difference in AEs may 
be due to issues with group matching rather than effects of 
QVA149.
In the SHINE study, the efficacy of QVA149 was tested 
against its components, indacaterol 150 μg, GLY 50 μg, 
as well as TIO 18 μg HandiHaler (Boehringer Ingelheim 
Pharmaceuticals, Inc., Ridgefield, CT, USA), and PCBO in a 
26-week trial of over 2,100 patients with moderate-to-severe 
COPD.54 QVA149 caused a rapid increase in FEV
1
 .100 mL 
at 5 minutes after the first dose. Trough FEV
1
 was increased for 
QVA149 vs all comparators, but vs active treatments, the FEV
1
 
improvements were 70–90 mL, approaching, but less than, 
accepted MCID for single agents. The proportion of patients 
who achieved a transition dyspnea index (TDI) score $1 was 
greater for QVA149 than PCBO and TIO, and the proportion of 
responders for St George Respiratory Questionnaire (SGRQ) 
improvements $8 was greater with QVA149 than PCBO, TIO, 
and GLY.55 Safety was similar in each group.
In the SPARK study, Wedzicha et al56 described the 
effect of QVA149 on exacerbation frequency in a group of 
patients with an FEV
1
 ,50% and at least one exacerbation 
in the last year, approximately 75% of the included patients 
were prescribed ICS at baseline. Exacerbations were strati-
fied as mild (self-managed at home), moderate (required 
corticosteroids and/or antibiotics), or severe (required hospi-
talization or an emergency room visit .24 hours). QVA149 
reduced all exacerbations 14% vs TIO (P=0.0017) and 15% 
vs GLY (P=0.012). Moderate and severe exacerbations were 
decreased by 12% QVA149 vs GLY (P=0.038), but the rate 
of moderate-to-severe AECOPD in the QVA149 group was 
not different than the TIO group. Compared to TIO and GLY, 
treatment with QVA149 improved health status for most of 
the 64-week trial.
In the ILLUMINATE trial, the effect of QVA149 vs 
salmeterol/fluticasone (SFC) (50/500 μg) was studied in 
patients with moderate-to-severe COPD without exacerbations 
in the past year.57 At week 26, FEV
1
 AUC
0–12 h
 was improved 
by 138 mL in the QVA149 group vs SFC (P,0.0001), with 
similar benefits in terms of FEV
1
 at 5 and 30 minutes post dose, 
FVC peak, trough, and AUC
0–12 h
. The mean scores for SGRQ 
were similar, and the TDI improved 0.76 units in the QVA149 
group, less than the MCID. Responder analysis showed that 
67.5% of the QVA149 group vs 56.8% of the SFC reported an 
improved TDI $1, for an odds ratio (OR) of 1.51 (P=0.046). 
Use of SABA was reduced by 0.39 puffs/day (P=0.019). 
There were no significant differences in AEs. In contrast to 
the GOLD recommendations, patients without a history of 
AECOPD are frequently documented to be prescribed ICS,58–60 
which would arguably increase cost and risk without sufficient 
likelihood of benefit in most cases. ILLUMINATE provides 
assurance that in similar patients, changing from ICS/LABA 
to LAMA/LABA would be safe and may improve control of 
symptoms. The study was not designed to assess the impact 
of this intervention on exacerbations.
QVA149 was compared to the free combination of 
TIO plus FOR in the QUANTIFY study, a Phase III trial 
of over 900 patients in Germany with moderate-to-severe 
COPD. QVA149 was noninferior in terms of exacerba-
tions, QOL, and mean dyspnea scores.61 Using responder 
analysis, dyspnea was improved with QVA149 (TDI $1 
QVA149 49.6% vs TIO/FOR 42.4%, P=0.033). In addition, 
QVA149 significantly improved predose FEV
1
 (68–72 mL) 
and FVC (74–106 mL) at weeks 12 and 26 when compared 
to TIO + FOR (P,0.05 for both), postdose FEV
1
 and FVC 
were similar.62
Dyspnea was the primary endpoint in the BLAZE study, 
a 3-period crossover study comparing QVA149, PCBO, and 
TIO. In the QVA149 group, dyspnea was improved with an 
OR for response by TDI of 1.78 vs TIO and 2.78 vs PCBO 
(P,0.005 for both). Additionally, FEV
1
, FVC, and rescue 
medication use were improved in the QVA149 group with 
similar safety outcomes.63
QVA149 has been shown to improve lung function, 
improve HRQOL and dyspnea, and, compared to TIO, 
reduce unreported exacerbations. It has been approved in 
Europe, Japan, Canada, and Latin America at a daily dose 
of 110/50 μg once daily. The EXPEDITION (FLIGHT 1, 
2, and 3) studies have been recently completed at a dose of 
QVA149 27.5/12.5 μg twice daily, a dose which has been 
submitted to the FDA for approval. The results are not cur-
rently reported.51
Aclidinium/formoterol
ACL, a novel muscarinic antagonist, has been combined with 
formoterol fumarate in a DPI device. The time required for 
dissociation of ACL from M3 receptors is between that of 
TIO and ipratropium, and it is dosed twice daily. Interest-
ingly, ACL is inactivated in plasma by hydrolysis, potentially 
decreasing side effects.22 The majority of published data is 
from two 24-week randomized, PCBO-controlled studies, 
AUGMENT COPD and ACLIFORM COPD.64,65 The drugs 
tested include twice-daily inhalation of aclidinium/formoterol 
(ACF) 400/12 μg (ACF12), ACF 400/6 μg (ACF6), FOR 
12 μg, ACL 400 μg, and PCBO.
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The ACLIFORM study65 compared ACF12, ACF6, ACL, 
FOR, or PCBO in 1,729 patients with stable moderate-to-
severe COPD. Both ACF12 and ACF6 increased trough and 
postdose FEV
1
, the higher dose preparation was generally 
more effective in bronchodilation. Curiously, the PCBO 
group experienced improvements in dyspnea and HRQOL 
above the MCID. Despite this, both ACF groups had a greater 
improvement in dyspnea and COPD symptoms compared to 
PCBO. HRQOL improved for all treatment groups (including 
PCBO) beyond the MCID, ranging -6.5 points for PCBO 
and -7.2 to -8.3 for the ACF12 and ACF6, respectively. 
Unreported exacerbations were reduced compared to PCBO 
in the ACF12 group (rate ratio 0.71, P#0.05), but AECOPD 
resulting in changes in management occurred infrequently 
and did not differ between groups. AEs were similar between 
groups, and no deaths were attributed to the study drug.
In AUGMENT COPD, dyspnea was improved in both 
doses of ACF vs PCBO (TDI .1), HRQOL was improved . 
MCID in the higher dose of ACF and in the ACL monotherapy 
group.66 In an extension of the AUGMENT trial, both doses of 
ACF were found to have a similar safety to PCBO over 1 year. 
Furthermore, combining the ACLIFORM and AUGMENT 
studies (total N=3,398) over 6 months showed that cardiovas-
cular events in both doses of ACF were similar to PCBO.67
One could conclude that ACF 400/12 μg inhaled twice 
daily increases FEV
1
 compared to PCBO, and improves 
dyspnea and HRQOL. The above studies show a decrease in 
unreported exacerbations compared to PCBO in the groups 
treated with ACF. Treatment appears to be safe. One could 
take advantage of twice-daily dosing in reducing nocturnal 
dyspnea, although this has not been specifically described 
to our knowledge for ACF.
Tiotropium/olodaterol
TIO/olodaterol (T/O) is the most recently approved LAMA/
LABA garnering approval by the FDA in May of 2015.68 It 
is delivered in the Respimat® Soft Mist Inhaler (Boehringer 
Ingelheim Pharmaceuticals, Inc.), which has been shown to 
provide good drug delivery over a wide range of flows. In a 
6-week crossover study of GOLD 2–4 COPD, T/O (5/5 and 
2.5/5 μg once daily) increased FEV
1
 (trough, 24-hour AUC), 
functional residual capacity, and decreased residual volume 
compared to monocomponents and PCBO.69 The magnitude of 
the effect on trough FEV
1
 benefit vs components (79–107 mL) 
was near or exceeded the MCID (all data not shown).
In a combined analysis of two replicate trials (TOnado 
1 and 2), TIO and olodaterol were compared at two 
doses TIO + olodaterol (T/O 5/5 or T/O 2.5/5 μg) to 
monocomponents olodaterol 5 μg, TIO 2.5 or 5 μg over 
52 weeks in patients with moderate to very severe COPD.70 
Primary analysis at 24 weeks showed that both doses 
improved lung function (FEV
1
 AUC
0–3
, trough FEV
1
) 
compared to monocomponents. Although improvements in 
trough FEV
1
 reached statistical significance, the differences 
were modest, ranging from 38 to 85 mL. QOL was improved 
by responder analysis of SGRQ. Dyspnea was improved 
in all groups (TDI focal score, 1.56–1.98), with statistical 
differences of the combination treatment over components, 
but differences between combination and component treat-
ments were uniformly ,1 unit. The study was not powered 
for exacerbations, but there was a trend toward reduced 
moderate-to-severe AECOPD in the combination group. 
The combination of TIO and olodaterol was found to have 
similar safety compared to monocomponents and did not 
differ between doses of TIO and olodaterol.
Glycopyrronium/formoterol
Glycopyrronium/formoterol (GFF) is a LAMA/LABA 
administered twice daily by metered dose inhaler (MDI). 
Two abstracts have been reported describing a 7-day Phase 
IIb trial comparing GFF 72/9.6 μg and GFF 36/9.6 μg to 
glycopyrrolate 36 μg MDI, FOR 9.6 μg MDI, FOR 7.2 μg 
MDI, TIO 18 μg DPI, FOR 12 μg DPI, and PCBO in 118 
patients with moderate to very severe COPD. Compared to 
all other agents and PCBO, GFF 72/9.6 μg produced greater 
FEV
1
 AUC
0–12 h
 on day 7, improving 103 mL vs TIO. This is 
important as GFF 72/9.6 μg compared favorably to both TIO 
and the monocomponents. GFF 36/9.6 μg was noninferior 
to the higher dose GFF 72/9.6 μg. Peak and trough FEV
1
 
were improved in both doses of GFF (data not available).71 
Both doses of GFF improved trough inspiratory capacity 
(90–105 mL) compared to TIO.71 The most frequent AE was 
dry mouth, similar to TIO. This agent is in Phase III develop-
ment by Pearl Therapeutics (Durham, NC, USA).
Bronchodilator activity and 
frequency of exacerbations
Currently approved bronchodilators shown to reduce COPD 
exacerbations include TIO, aclidinium bromide, salmeterol, 
SFC, and budesonide/formoterol.18,72 Information regarding 
relative efficacy of these agents is limited. The largest trial, 
POET-COPD, found that TIO was more effective than sal-
meterol in preventing COPD exacerbations.73 In a 2-year trial, 
no difference in exacerbation rate was shown when TIO was 
compared to SFC.74 Agents in development would optimally 
prove superior to these agents at a lower cost with increased 
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safety, while yielding other benefits such as improvement 
in dyspnea and HRQOL. Exacerbation frequency has been 
reported for QVA149, UMEC/VI, and ACF. In pooled data 
from two prospective 24-week studies (AUGMENT and 
ACLIFORM), ACF 400/12 μg dosed twice daily was noted to 
reduce COPD exacerbations rates by 0.70–0.79 vs PCBO.75
The SPARK trial compared QVA149 to GLY 50 μg or 
TIO 18 μg HandiHaler in 2,224 patients, with a mean FEV
1
 
of 37% and at least one exacerbation in the prior year. The 
primary outcome was COPD exacerbations, and the study 
was planned for 64 weeks, but was extended to 74 weeks 
to increase exacerbation events, which were lower than 
expected. QVA149 reduced all exacerbation rates compared 
to both GLY (reduced 15%, P=0.012) and TIO (reduced 14%, 
P=0.0017). Compared to TIO, QVA149 achieved statistically 
significant reductions only in mild exacerbations, defined 
as being self-managed at home without steroids or antibiot-
ics. QVA149 reduced moderate or severe exacerbation rate 
compared to GLY.56 Interestingly, unreported AECOPD are 
both frequent and negatively impact health status.76
There are conflicting results regarding the prevention of 
AECOPD by using UMEC/VI. In a 24-week trial comparing 
UMEC/VI 62.5/25 μg to PCBO and components, the hazard 
ratio for time to first COPD exacerbation was 0.5 (P#0.01) 
vs PCBO.43 In a second 52-week trial comparing UMEC/VI 
125/25 μg to UMEC 125 μg or PCBO, hospitalizations were 
reduced in both treatment groups (6%–7%) vs PCBO (12%). 
Although this is an important finding, the authors note that 
the aforementioned studies were not designed to study this 
outcome.46 In a trial of 1,493 patients with a mean FEV
1
 of 
55%, UMEC/VI 125/25 μg was compared to components 
UMEC 125 μg, VI 25 μg, and PCBO. Compared to PCBO, 
all treatments reduced the risk of AECOPD (HR: 0.4–0.5, 
P#0.006 for all vs PCBO).47 COPD exacerbations were 
defined as acute worsening, requiring emergency treatment 
beyond increasing home ALB. Finally, in two paired 24-week 
trials totaling 1,718 patients with a mean FEV
1
 of 47%–48%, 
there were no differences in the time to first AECOPD between 
groups treated with UMEC/VI 125/25 μg, UMEC/VI 62.5/ 
25 μg, TIO 18 μg, VI 25 μg, or UMEC 125 μg.44 The avail-
able evidence suggests that UMEC/VI 125/25 μg prevents 
AECOPD compared to PCBO, and UMEC/VI 62.5/25 μg may 
prevent AECOPD compared to PCBO. The reader is reminded 
that the approved doses are at or less than the latter.
Prospects, real world evidence
In 2013, best selling drugs included SFC at second place 
and TIO at 12th.77 ICS/LABAs are frequently prescribed to 
patients at low risk for exacerbation, 18% of GOLD group B 
patients were prescribed ICS/LABA in one questionnaire.78 
The combination of LAMA/LABA may provide an alternate 
combination medication to optimize therapeutic goals and 
avoid the risks and costs of ICS. In the recently published 
WISDOM trial comparing ICS + LABA + LAMA, vs 
stepdown to LAMA/LABA alone, noninferiority was dem-
onstrated for the outcome of COPD exacerbations.79 In the 
future, identification of COPD phenotypes may allow clini-
cians to personalize bronchodilator prescription.
TIO has occupied the center stage for the management 
of COPD for the last decade. Presumably, the appeal of new 
agents for patients will be improvement in symptoms, reduced 
cost, and increased convenience. For physicians, reductions 
in AECOPD and adherence are likely to be important factors 
as well. In the SHINE study, QVA149 produced a rapid onset 
of bronchodilation, improved dyspnea, and QOL compared to 
PCBO and TIO.54 Although UMEC/VI 125/25 μg improved 
FEV
1
, patient symptoms (dyspnea and HRQOL) did not 
improve compared to TIO alone.44 In TOnado, the combina-
tion of T/O improved dyspnea compared to TIO.80
Efficacy is a moot issue without adherence, a significant 
problem in COPD treatment.81 Generally, adherence increases 
with a simpler dosing regimen (once daily . multiple times, 
single inhaler vs multiple) and in the presence of immedi-
ate symptom relief. In addition, ease of device use is an 
important factor, in one study, over 40% of the patients 
hospitalized failed at least one element of inhaler technique.82 
Effective use of any inhaled medication depends on patient 
and physician education regarding proper technique, proper 
counseling, and follow-up with the patient. Combining bron-
chodilators streamlines the number of medications and dosing 
frequency the patient must recall, understand, and schedule 
into their daily routine and has the potential to limit toxicity 
through the use of lower dosages of both.
New directions
Devices
Novel devices are developed for inhaled bronchodilators in 
COPD; agents can be given individually as free inhalers or 
combined with another agent in a fixed-drug combination 
(FDC). All of the new therapies will be available in FDCs. 
There are some nuances in use of inhaler devices, in order to 
effectively and safely deliver therapy directly to the lung. Also, 
drug/drug interactions in new FDCs are carefully studied as the 
combinations are compared to the free drug inhalers by them-
selves. Many novel devices such as Ellipta® (GlaxoSmithKline 
plc, Durham, NC, USA) have been developed, and each type 
of device has its own advantages and perhaps a few have dis-
advantages. A pressurized MDI, with a cosuspension of GFF, 
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a new upcoming FDC, is in the final stages of clinical trials at 
the present time. Others, such as the combination of T/O, will 
be in a soft mist device (Respimat®), while most others are in 
DPIs. The most important aspect is tailoring the device to the 
patients’ physical condition, needs, and preferences.
MABAs and triples
One exciting development in the dual bronchodilator story 
is the potential use of dual agents or bifunctional muscar-
inic antagonists and β
2
-agonists (MABAs) that are single 
molecule antimuscarinic and adrenergic agents. Clinical 
trials have established the efficacy and safety of these novel 
agents, and clinical development is progressing. MABAs 
may provide a pathway for triple therapy (provided by these 
agents) by adding an ICS. Also, the Ellipta® device is being 
tested with UMEC and the ICS/LABA fluticasone furoate 
and VI. Initial studies show additional bronchodilation with 
the triple combination, and the exacerbation results are pend-
ing. The WISDOM study however shows that one can do the 
opposite safely, reduce from triple to dual therapy without 
increasing exacerbations.79
Nebulizer combinations
One exciting area in research is the use of combinations in 
nebulizers for patients with COPD. Nebulizers enable higher 
doses of drugs to be used. Also, the nebulized aerosol may 
be delivered with a mask, which can be easier for older and 
weaker patients to use. Patients who are impaired, as well as 
those with low inspiratory flows, may also benefit from the 
nebulizers. New ultrasonic devices are being evaluated that 
will be more efficient than older devices. Presently, combina-
tions of 12-hour LABAs such as FOR and arformoterol are 
being tested with LAMAs such as GLY and novel LAMAs. 
Previous studies of LAMA/LABAs using separate devices 
showed added improvement. These combinations, if effective 
and safe, will be very convenient for patients to use; one of 
the disadvantages with nebulizers was the long time needed 
to complete nebulization of two free drugs. Also, new com-
binations may include novel agents like anti-inflammatory 
drugs or mucolytics combined with bronchodilators. For 
example, agents that have side effects when given orally, 
such as phosphodiesterase-4 inhibitors, may be combined 
in an inhaled form within an inhaled β-agonist. The inhaled 
β-agonist may offset some of the acute effects of nonbron-
chodilators, transiently reducing FEV
1
.
Conclusion
The addition of LAMA/LABA in a single inhaler device 
offers a significant new approach to therapy. There is clear 
evidence that patients with COPD are excessively prescribed 
ICS/LABA combinations. Emerging evidence that stopping 
ICS is safe for some patients further assures the clinician 
that treatment with a LAMA/LABA would be reasonable. 
Patients with dyspnea despite the use of either a LAMA 
or LABA may have improvement in HRQOL, dyspnea, 
and reduced rescue medication use with LAMA/LABA. 
Additionally, some agents have reported improvement in 
exacerbations. Similar to the Goldilocks principle, we search 
for therapies that are “just right” for the individual patient. 
With the addition of LAMA/LABA, there are now more 
bowls at the table.
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